TEL AVIV, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at two Israeli conferences in May, 2014.
| Oppenheimer 15th Annual Israeli Investor Conference | |
| Date: | Sunday, May 11, 2014 |
| Time: | 7:10am Eastern/1:10pm GMT +2 |
| Location: | David Intercontinental Hotel in Tel-Aviv |
| MIXiii/BioMed Israel Innovation Conference | |
| Date: | Wednesday, May 21, 2014 |
| Panel Title: | "Riding the IPO Wave" |
| Time: | 9am Eastern/3pm GMT +2 |
| Company Presentation | 11am Eastern/5pm GMT +2 |
| Location: | Tel-Aviv Fairgrounds |
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder, and is enrolling patients in a Phase III study for this indication in adults. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.